Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24346285 | 1.00 | OPRL1 (0.38) | OPRL1TAAR1RORCGPR119ABCB1 | |
| SCHEMBL30623219 | 0.85 | OPRL1 (0.41) | OPRL1TAAR1RORCGPR119KDM1A | |
| SCHEMBL26062015 | 0.85 | OPRL1 (0.41) | OPRL1TAAR1RORCGPR119KDM1A | |
| SCHEMBL31387359 | 0.85 | OPRL1 (0.41) | OPRL1TAAR1RORCGPR119KDM1A | |
| SCHEMBL26059137 | 0.85 | OPRL1 (0.41) | OPRL1TAAR1RORCGPR119KDM1A | |
| SCHEMBL24346232 | 0.82 | OPRL1 (0.39) | OPRL1TAAR1RORC | |
| SCHEMBL29413716 | 0.82 | OPRL1 (0.39) | OPRL1TAAR1RORC | |
| SCHEMBL29413710 | 0.82 | — | — | |
| SCHEMBL24344882 | 0.80 | RORC (0.32) | OPRL1RORC | |
| SCHEMBL29413702 | 0.80 | RORC (0.32) | OPRL1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421249-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240368180-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2024-11-07 | — | — | US | disclosed |
| US-11866446-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4204423-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2022047031-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, APOB | OPRL1 453/4885TAAR1 3308/4885RORC 3725/4885 |
| US-12421249-B2 | Inhibitors of APOL1 and methods of using same | APOL1, PNLIP, APOB | OPRL1 453/4885TAAR1 3308/4885RORC 3725/4885 |
| US-20240368180-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, APOB | OPRL1 453/4885TAAR1 3308/4885RORC 3725/4885 |
| US-11866446-B2 | Inhibitors of APOL1 and methods of using same | APOL1, PNLIP, APOB | OPRL1 453/4885TAAR1 3308/4885RORC 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.